BC Platforms Selected as Partner to Deliver key Singapore Population Health Study

3 weeks ago 36

First-in-kind Singapore study to deliver insights into heart disease, diabetes, cancer, and other chronic diseases

/EIN News/ -- ZURICH, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced it has been selected as the platform of choice to analyse and manage data collected from the Health for Life in Singapore (HELIOS) study, which forms part of the SG100K data set for Singapore's National Precision Medicine programme.

The HELIOS study is a state-of-the-art population cohort study established and led by the Lee Kong Chian School of Medicine (LKCMedicine) at Nanyang Technological University, Singapore (NTU Singapore). The population study aims to identify environmental, lifestyle and genetic factors that cause heart disease, diabetes, cancer, and other chronic diseases in Singapore.

As part of Singapore’s SG100K study, the HELIOS study will recruit up to 50,000 men and women, aged 30-84 years old, from the Singapore population progressively over the next two years. BCP will be providing BC|INSIGHT and BC|RQUEST for management of LKCMedicine’s genotype and phenotype patient data from a large Asian cohort in a safe and secure manner.

Bringing access to the HELIOS-SG100K data through BC platforms will enable and accelerate researchers to pursue key questions around precision health and personalised medicine.

Nino da Silva, Deputy Managing Director, BC Platforms, said, “I’m delighted that we have more good news coming out of Singapore, a major focus for deploying our clinical solutions and driving precision medicine, where we are working with leading Asian healthcare institutions. This latest partnership should make it easier for health service providers to determine optimal patients treatment pathways in major diseases areas, based on population health insights using our genomic data management platform. Asia’s rich multi-ethnicity is of great value for life science research and clinical decision making.”

NTU LKCMedicine’s Professor John Chambers, Lead Investigator of SG100K, said, “The unique and extensive measurements and samples collected, together with long term follow-up will enable the investigation of the complex interrelationships between environmental, lifestyle and genetic factors on subsequent disease risk. The HELIOS s...

Read Entire Article